Cargando…

Drug Repurposing for Rare Diseases: A Role for Academia

Background: The European Commission highlights in its Pharmaceutical Strategy the role of academic researchers in drug repurposing, especially in the development of orphan medicinal products (OMPs). This study summarizes the contribution of academia over the last 5 years to registered repurposed OMP...

Descripción completa

Detalles Bibliográficos
Autores principales:	van den Berg, Sibren, de Visser, Saco, Leufkens, Hubert G.M., Hollak, Carla E.M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564285/ https://www.ncbi.nlm.nih.gov/pubmed/34744726 http://dx.doi.org/10.3389/fphar.2021.746987

Ejemplares similares

Access to medicines for rare diseases: A European regulatory roadmap for academia
por: Rosenberg, Noa, et al.
Publicado: (2023)

Registries for orphan drugs: generating evidence or marketing tools?
por: Hollak, Carla E. M., et al.
Publicado: (2020)

Enrichment analysis of phenotypic data for drug repurposing in rare diseases
por: Ambesi-Impiombato, Alberto, et al.
Publicado: (2023)

Current Drug Repurposing Strategies for Rare Neurodegenerative Disorders
por: Shah, Sweta, et al.
Publicado: (2021)

Natural products and drug discovery: a survey of stakeholders in industry and academia
por: Amirkia, Vafa, et al.
Publicado: (2015)

Getting the Right Evidence After Drug Approval
por: Vreman, Rick A., et al.
Publicado: (2020)

On the Integration of In Silico Drug Design Methods for Drug Repurposing
por: March-Vila, Eric, et al.
Publicado: (2017)

Editorial: Drug Repurposing for COVID-19 Therapy
por: Maldonado, Rafael, et al.
Publicado: (2021)

Disulfiram in glioma: Literature review of drug repurposing
por: Zhong, Shiyu, et al.
Publicado: (2022)

Screening of GPCR drugs for repurposing in breast cancer
por: Abdulkareem, Noor Mazin, et al.
Publicado: (2022)

Navigating drug repurposing for Chagas disease: advances, challenges, and opportunities
por: Porta, Exequiel O. J., et al.
Publicado: (2023)

Editorial: The challenges of drug repurposing in diseases related to chronic inflammation
por: Collotta, Debora, et al.
Publicado: (2023)

“Hard” Drug Repurposing for Precision Oncology: The Missing Link?
por: Pantziarka, Pan, et al.
Publicado: (2018)

Challenges for Drug Repurposing in the COVID-19 Pandemic Era
por: Sultana, Janet, et al.
Publicado: (2020)

Fingolimod and Diabetic Retinopathy: A Drug Repurposing Study
por: Gesualdo, Carlo, et al.
Publicado: (2021)

A Database of Drug Repurposing Clinical Trials in Oncology
por: Pantziarka, Pan, et al.
Publicado: (2021)

Editorial: Translational Research and Drug Repurposing for Non-Communicable Diseases (NCDs)
por: Akindele, Abidemi J., et al.
Publicado: (2022)

Repurposing Anti-Malaria Phytomedicine Artemisinin as a COVID-19 Drug
por: Uckun, Fatih M., et al.
Publicado: (2021)

Drug Repurposing of the Anthelmintic Niclosamide to Treat Multidrug-Resistant Leukemia
por: Hamdoun, Sami, et al.
Publicado: (2017)

Repurposing Cefazolin-Avibactam for the Treatment of Drug Resistant Mycobacterium tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2021)

Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery
por: Li, Xinlei, et al.
Publicado: (2021)

Editorial: Cancer neuroscience: Drug repurposing targeting the innervated niche
por: Jin, Ming-Zhu, et al.
Publicado: (2023)

Drug repurposing in cardiovascular inflammation: Successes, failures, and future opportunities
por: Chaffey, Laura, et al.
Publicado: (2022)

Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile
por: Wang, Ting, et al.
Publicado: (2022)

Repurposing of Pirfenidone (Anti-Pulmonary Fibrosis Drug) for Treatment of Rheumatoid Arthritis
por: Gan, Donghao, et al.
Publicado: (2021)

Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge?
por: Ma, Zhaowu, et al.
Publicado: (2021)

Drug repurposing candidates to treat core symptoms in autism spectrum disorder
por: Koch, Elise, et al.
Publicado: (2022)

Target-specific compound selectivity for multi-target drug discovery and repurposing
por: Wang, Tianduanyi, et al.
Publicado: (2022)

Barbiturates and pyrazolopyridines for the treatment of postpartum depression—repurposing of two drug classes
por: Horwitz, Alexander B., et al.
Publicado: (2023)

Editorial: Drug repurposing and polypharmacology: A synergistic approach in multi-target based drug discovery
por: Rudrapal, Mithun, et al.
Publicado: (2022)

Drug Shortages From the Perspectives of Authorities and Pharmacy Practice in the Netherlands: An Observational Study
por: Postma, Doerine J., et al.
Publicado: (2018)

Expert-Augmented Computational Drug Repurposing Identified Baricitinib as a Treatment for COVID-19
por: Smith, Daniel P., et al.
Publicado: (2021)

Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021
por: Alam, Safaet, et al.
Publicado: (2021)

Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2
por: Chen, Catherine Z., et al.
Publicado: (2021)

The Role of Propranolol as a Repurposed Drug in Rare Vascular Diseases
por: Cuesta, Angel M., et al.
Publicado: (2022)

Drug repurposing for Alzheimer’s disease from 2012–2022—a 10-year literature review
por: Grabowska, Monika E., et al.
Publicado: (2023)

The Regulatory Challenges for Drug Repurposing During the Covid-19 Pandemic: The Italian Experience
por: Gozzo, Lucia, et al.
Publicado: (2020)

Repurposing Clinical Drugs as AdoMetDC Inhibitors Using the SCAR Strategy
por: Zhang, Yan, et al.
Publicado: (2020)

Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements
por: Frega, Giorgio, et al.
Publicado: (2020)

Modeling of SARS-CoV-2 Treatment Effects for Informed Drug Repurposing
por: Kern, Charlotte, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p2vetavbpe6tuoq5ojtunh5esb